Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study

Objective:To evaluate efficacy and safety of intravitreal bevacizumab (Avastin) in eyes with macular oedema secondary to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO).Methods:Twenty-eight consecutive patients (28 patients, 29 eyes, 8 CRVO, 21 BRVO) were enrolled in th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of ophthalmology 2008-04, Vol.92 (4), p.518-522
Hauptverfasser:	Kriechbaum, K, Michels, S, Prager, F, Georgopoulos, M, Funk, M, Geitzenauer, W, Schmidt-Erfurth, U
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Bevacizumab Biological and medical sciences Diabetic retinopathy Drug Administration Schedule Drug dosages Female Humans Injections Lasers Macular Edema - drug therapy Macular Edema - etiology Macular Edema - physiopathology Male Medical sciences Middle Aged Miscellaneous Ophthalmology Prospective Studies Retinal Vein Occlusion - complications Retinopathies Studies Tomography, Optical Coherence Treatment Outcome Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - drug effects Vitreous Body
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objective:To evaluate efficacy and safety of intravitreal bevacizumab (Avastin) in eyes with macular oedema secondary to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO).Methods:Twenty-eight consecutive patients (28 patients, 29 eyes, 8 CRVO, 21 BRVO) were enrolled in the study. Three intravitreal injections of 1 mg bevacizumab (0.04 ml) were administered at 4-week intervals; further retreatment was based on optical coherence tomography (OCT) findings. Follow-up examinations were done at days 1, 7 and 28 and at monthly intervals thereafter.Results:Mean baseline central retinal thickness (CRT) in OCT was 558 µm (range 353–928 µm) and mean BCVA was 20/100. One day after the first injection, CRT significantly decreased to 401 μm (p
ISSN:	0007-1161 1468-2079
DOI:	10.1136/bjo.2007.127282